fbpx Ata Plus - SENTRY

SENTRY

Malaysia’s FIRST Healthcare & Wellness centric marketplace. Becoming a one stop solution for all healthcare needs with the largest healthcare product selection & services. We help one look after their own health effortlessly as well as take care of loved ones wherever they may reside in Malaysia. 

RM 600,000 raised
100% Complete
100% of target 1 month left
Investors4
Min Target RM 600,000
Max TargetRM 2,000,000
Log In to Invest

Introduction

Sentry is an online store provider of medicines and healthcare products. It provides an online platform that offers prescription, over-the-counter drugs and healthcare and wellness products. It allows users to buy various healthcare products such as skincare, family care, baby care and many more. Apart from being an online store, Sentry also provide verified localized health articles from health experts and allow users to book online doctor consultation and lab tests too.


What We Do

The Challenge

The healthcare industry has not changed much since decades ago. For years, access to quality healthcare has been a challenge for most of us and with the demands on our lives now, it is all the more important that we get comprehensive and timely healthcare from one place.

Our Solution

Meeting the inadequacies in the healthcare delivery system through technological interventions. The healthcare marketplace startup aims at providing a platform which would enable a consumer to gain access to healthcare services at all levels, starting from having all their clinic visits and prescriptions recorded and stored to buy medicines online and getting them delivered to their doorstep to e-consultation with doctors and scheduling diagnostic tests, thereby making it a one-stop platform for healthcare needs.


Why Are We Different

Competitive Landscape

 

Competitive Landscape

 


Our Revenue Model

  • Subscription

    • Freemium vendor to Premium vendor

    • Marketplace Profit Sharing

    • Supplement and Medications

  • Digital Ads

    • Virtual Space / Virtual Real Estate (VRE)

    • Programmatic Ad Serving


Our Market Opportunity

The global pharmaceuticals market was worth RM 4.08 trillion (USD $934.8 billion) in 2017, and will reach RM 5.107 trillion (USD $1.17 trillion) in 2021, growing at 5.8%. Domestically, the Malaysian pharmaceutical market is forecasted to grow from RM 10.039 billion (USD $2.3 billion) in 2015 to RM 15.714 billion (USD $3.6 billion) by 2020, representing a compound annual growth rate (CAGR) of 9.5%.

Source: The Business Research (2018), GlobalData (2016), CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia.


Our Strategy

 

short term

 

LOng Term

 

 

Medium Term

 

 


Indicative Usage of Funds

Use of Funds

 

Use of Funds

 


The Team

Mak Kinn Lian

Chief Executive Officer

A serial entrepreneur specializing in early stage start-ups investments, who has intense enthusiasm to improve quality of life and wellbeing of everyone.

Michelle Koo

Chief Operating Officer

With over 8 years of experience in eCommerce building the B2C, B2B & B2E sectors for multiple MNCs & SMEs. She has experiences in multiple roles in eCommerce from Business Development, Operations to Web Development & Key Account Manager.

Term Sheet

Risk Disclaimer

Investing in equity crowdfunding involves certain risks that include uncertainty of returns, lack of liquidity, dilution, material events and lack of control. Investments should be done as part of a diversified portfolio. ATA PLUS offers investment opportunities to investors who understands these risks in making their own investment decisions.

PLEASE READ THE FULL RISK WARNING BEFORE DECIDING TO INVEST.

This page is approved as a financial promotion by ATA PLUS Sdn. Bhd., which is authorized and regulated by the Security Commission of Malaysia. Deals that are up for investment are only offered to members of ata-plus.com on the basis of information provided by the companies concerned. ATA PLUS takes no responsibility for this information or for any recommendations or opinions made by the companies. For further information on this, please read our Term of Use.